Nicholas Leupin's most recent trade in NovoCure Ltd was a trade of 81,499 Stock Options (Right to buy) done . Disclosure was reported to the exchange on March 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NovoCure Ltd | Nicholas Leupin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 81,499 | 81,499 | - | - | Stock Options (Right to buy) | |
| NovoCure Ltd | Nicholas Leupin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 18.19 per share. | 04 Mar 2025 | 54,975 | 105,108 (0%) | 0% | 18.2 | 999,995 | Ordinary Shares |
| NovoCure Ltd | Nicholas Leupin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.92 per share. | 27 Feb 2025 | 830 | 50,294 (0%) | 0% | 19.9 | 16,535 | Ordinary Shares |
| NovoCure Ltd | Nicholas Leupin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.55 per share. | 27 Feb 2025 | 161 | 50,133 (0%) | 0% | 20.5 | 3,308 | Ordinary Shares |
| NovoCure Ltd | Nicholas Leupin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 78,174 | 78,174 | - | - | Stock Options (Right to buy) | |
| NovoCure Ltd | Leupin Nicholas | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 16.30 per share. | 27 Feb 2024 | 51,124 | 51,124 (0%) | 0% | 16.3 | 833,321 | Ordinary Shares |